The CMO/CDMO Market encompasses a broad range of outsourced pharmaceutical development and manufacturing services. Market Research Future estimates that the market will reach USD 50.89 billion by 2035 from USD 27.08 billion in 2024, growing at a CAGR of 5.9% during 2025–2035.

The market can be analyzed by service type, product type, application, and end use. Service categories include contract manufacturing, contract development, process development, analytical services, and packaging services. These services enable pharmaceutical and biotechnology companies to access specialized capabilities without developing all manufacturing infrastructure internally.

By product type, the market includes active pharmaceutical ingredients, biologics, small molecules, and intermediates. Biologics represent an important opportunity because the development of complex biological therapies requires highly specialized facilities, expertise, and quality systems.

Applications include pharmaceutical manufacturing, biologics production, chemical synthesis, contract research, and process development. Pharmaceutical companies remain major users of outsourcing services, while biotechnology firms increasingly depend on CDMOs for development and commercialization support.

The competitive environment includes major global organizations such as Lonza, Samsung Biologics, Boehringer Ingelheim, Catalent, WuXi AppTec, Fujifilm Diosynth Biotechnologies, Recipharm, Aenova Group, and Siegfried.

Competition is increasingly focused on manufacturing capacity, technological capabilities, regulatory expertise, quality systems, and integrated services.

As drug pipelines become more complex, CMO/CDMO providers with end-to-end capabilities are expected to gain attractive opportunities across the pharmaceutical industry.